Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Azzi on the Unmet Needs the Signatera ctDNA Assay Could Fulfill in CRC

January 20th 2022

Georges Azzi, MD, discusses the unmet needs the Signatera circulating tumor DNA assay could fulfill in colorectal cancer.

Dr. Lenz on the Rationale for the CheckMate 9X8 Trial in Metastatic CRC

January 20th 2022

Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.

Dr. Kopetz on the Rationale for the BREAKWATER Trial in BRAF V600E-Mutant mCRC

January 20th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.

Next Steps for KRAS Inhibitors Focus on Tackling Resistance

January 17th 2022

The recent approval of sotorasib for the treatment of patients with advanced KRAS G12C–mutant non–small cell lung cancer marks a milestone for cancer therapy.

Dr. Weiss on the Design of the KRYSTAL-10 Trial in KRAS G12C-Mutated CRC

January 17th 2022

Jared Weiss, MD, discusses the design of the phase 3 KRYSTAL-10 trial in KRAS G12C-mutated unresectable or metastatic colorectal cancer.

Dr. Azzi on the Rationale for the CIRCULATE Study in CRC

January 14th 2022

Georges Azzi, MD, discusses the rationale for the phase 3 CIRCULATE study in colorectal cancer.

Dr. Spaggiari on Surgical Strategies to Improve Liver Remnants in CRC With Liver Metastases

January 13th 2022

Mario Spaggiari, MD, discusses surgical strategies to improve liver remnants in colorectal cancer with liver metastases.

Adagrasib With or Without Cetuximab Produces Encouraging Clinical Activity in KRAS G12C–Mutant CRC

January 13th 2022

Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.

Dr. Bekaii-Saab on the Promise of Non–VEGF Inhibitor Platforms in HCC

January 12th 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the promise of non–VEGF inhibitor platforms in hepatocellular carcinoma.

Dr. Mulcahy on the Design of the EPOCH Trial in mCRC With Liver Metastases

January 11th 2022

Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.

Dr. Spaggiari on Considerations for Patients With CRC and Liver Metastases Without Surgical Options

January 10th 2022

Mario Spaggiari, MD, discusses considerations for patients with colorectal cancer and liver metastases who have no surgical options.

Dr. Ciombor on Rechallenging With EGFR Inhibitors in RAS/RAF Wild-Type CRC

January 7th 2022

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

Hepatectomy Plus Adjuvant mFOLFOX6 Improves DFS in Liver-Only Metastatic CRC

January 6th 2022

Adjuvant chemotherapy with modified fluoropyrimidine, leucovorin, and oxaliplatin improved disease-free survival among patients with liver-only metastases from colorectal cancer who were treated with hepatectomy.

Anti-EGFR Treatment Grows in Prominence for CRC

January 4th 2022

With an influx of new trials examining the use of anti-EGFR treatments in patients with advanced colorectal cancer, attention must be paid to finding the optimal window in which to give these therapies to maximize benefit.

Dr. Jain on the Push Toward Personalized Treatment Approaches in CRC With Liver Metastases

January 3rd 2022

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.

Dr. Spaggiari on the Potential Utility of Liver Transplantation in CRC With Liver Metastases

December 23rd 2021

Mario Spaggiari, MD, discusses the potential utility of liver transplantation as a treatment option for patients with colorectal cancer liver metastases.

Dr. Bekaii-Saab on the Benefits Derived With Bevacizumab Plus TAS-102 in mCRC

December 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

Dr. Jain on the Importance of Communication for Multidisciplinary Care in CRC

December 21st 2021

Shikha Jain, MD, FACP, discusses the importance of communication in patients with colorectal cancer and liver metastases who are receiving multidisciplinary care.

Dr. Shirasu on the Clinical Implications of ctDNA in CRC

December 20th 2021

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Surgical Resectability Remains Crucial in Determining Treatment Strategy in Liver-Only Metastatic CRC

December 20th 2021

Early identification of patients with liver-only metastatic colorectal cancer who are eligible for resection is crucial to determining their course of treatment and what role modalities like chemotherapy will play in their treatment strategy.